Predict your next investment

HEALTHCARE | Biotechnology
immunocore.com

See what CB Insights has to offer

Total Raised

$743.66M

Investors Count

14

Deal Terms

3

Immunocore Funding, Immunocore Valuation & Immunocore Revenue

8 Fundings

Immunocore's latest funding round was a IPO for $258.33M on February 5, 2021.

Immunocore's latest post-money valuation is from February 2021.

Sign up for a free 30-day trial to see Immunocore's valuations in February 2021 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

2/5/2021

IPO

$258.33M

$99M

$0.00B

((9.99x))

FY 1234

3

1/12/2021

Line of Credit

$99M

$0.00B

((9.99x))

FY 1234

10

1/12/2021

Series C

$99M

$0.00B

((9.99x))

FY 1234

10

3/2/2020

Series B

$99M

$0.00B

((9.99x))

FY 1234

10

9/20/2019

Growth Equity

$99M

$0.00B

((9.99x))

FY 1234

10

Date

2/5/2021

1/12/2021

1/12/2021

3/2/2020

9/20/2019

Round

IPO

Line of Credit

Series C

Series B

Growth Equity

Amount

$258.33M

$99M

$99M

$99M

$99M

Investors

Valuation

$99M

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

3

10

10

10

10

Immunocore Deal Terms

3 Deal Terms

Immunocore's deal structure is available for 3 funding rounds, including their IPO from February 05, 2021.

Round

IPO

Growth Equity

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

IPO

$99M

$99M

$99M

$99M

$99M

$99M

Growth Equity

$99M

$99M

$99M

$99M

Series A

Immunocore Investors

14 Investors

Immunocore has 14 investors. RTW Investments invested in Immunocore's Series B funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

7/16/2015

3/2/2020

2
Series A, Series B (2020)

Hedge Fund

New York

9/18/2017

3/2/2020

2
Grant - II, Series B (2020)

Non-Profit Foundation

Washington

9/20/2019

3/2/2020

2
Growth Equity, Series B (2020)

Growth Equity

Connecticut

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Corporation

Indiana

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

New York

First funding

7/16/2015

9/18/2017

9/20/2019

00/00/0000

00/00/0000

Last Funding

3/2/2020

3/2/2020

3/2/2020

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Rounds

2
Series A, Series B (2020)
2
Grant - II, Series B (2020)
2
Growth Equity, Series B (2020)

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Type

Hedge Fund

Non-Profit Foundation

Growth Equity

Corporation

Venture Capital

Location

New York

Washington

Connecticut

Indiana

New York

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.